Literature DB >> 21663839

Molecular mechanisms for insulin resistance in treated HIV-infection.

Paul W Hruz1.   

Abstract

Identification and characterization of the molecular mechanisms contributing to the high incidence of insulin resistance in HIV infected patients treated with combined antiretroviral therapy remains a critically important goal in the quest to improve the safety of antiretroviral treatment regimens. The use of in vitro model systems together with the investigation of drug-mediated effects on glucose homeostasis in animals and healthy human volunteers has provided important insight into the contribution of individual drugs to insulin resistance and affected cellular pathways. HIV protease inhibitor mediated blockade of glucose transport and nucleoside reverse transcriptase inhibitor mediated mitochondrial toxicity have been well characterized. Together with growing understanding of mediators of insulin resistance in non-HIV metabolic syndrome, additional cellular effects including the induction of endoplasmic reticulum and oxidative stress, altered adipocytokine secretion, and lipotoxicity have been integrated into this developing picture. Further elucidation of these mechanisms provides potential for the continued development of safer antiviral drugs and targeted treatment of insulin resistance in affected patients.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21663839      PMCID: PMC3115529          DOI: 10.1016/j.beem.2010.10.017

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  84 in total

1.  Inhibition of adipocyte differentiation by HIV protease inhibitors.

Authors:  B Zhang; K MacNaul; D Szalkowski; Z Li; J Berger; D E Moller
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

2.  Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies.

Authors:  Grace A McComsey; Ulrich A Walker
Journal:  Mitochondrion       Date:  2004-07       Impact factor: 4.160

3.  Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy.

Authors:  Georg M N Behrens; Anne-Rose Boerner; Klaus Weber; Joerg van den Hoff; Johann Ockenga; Georg Brabant; Reinhold E Schmidt
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

4.  Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.

Authors:  Seng Khee Gan; Katherine Samaras; Campbell H Thompson; Edward W Kraegen; Andrew Carr; David A Cooper; Donald J Chisholm
Journal:  Diabetes       Date:  2002-11       Impact factor: 9.461

5.  Indinavir induces acute and reversible peripheral insulin resistance in rats.

Authors:  Paul W Hruz; Haruhiko Murata; Haijun Qiu; Mike Mueckler
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

Review 6.  Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation.

Authors:  Eoin R Feeney; Patrick W G Mallon
Journal:  Curr Pharm Des       Date:  2010-10       Impact factor: 3.116

7.  Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.

Authors:  Simon P Jones; Nadeem Qazi; John Morelese; Dirk Lebrecht; Jussi Sutinen; Hannele Yki-Jărvinen; David J Back; Munir Pirmohamed; Brian G Gazzard; Ulrich A Walker; Graeme J Moyle
Journal:  J Acquir Immune Defic Syndr       Date:  2005-12-15       Impact factor: 3.731

8.  Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes.

Authors:  Zhanguo Gao; Xiaoying Zhang; Aamir Zuberi; Daniel Hwang; Michael J Quon; Michael Lefevre; Jianping Ye
Journal:  Mol Endocrinol       Date:  2004-05-13

9.  HIV protease inhibitors acutely impair glucose-stimulated insulin release.

Authors:  Joseph C Koster; Maria S Remedi; Haijun Qiu; Colin G Nichols; Paul W Hruz
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

Review 10.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

View more
  19 in total

Review 1.  Endocrinological aspects of HIV infection.

Authors:  F S Mirza; P Luthra; L Chirch
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

Review 2.  Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.

Authors:  Ann A Verhaegen; Luc F Van Gaal
Journal:  Curr Obes Rep       Date:  2021-01-05

3.  Isoform-selective inhibition of facilitative glucose transporters: elucidation of the molecular mechanism of HIV protease inhibitor binding.

Authors:  Richard C Hresko; Thomas E Kraft; Anatoly Tzekov; Scott A Wildman; Paul W Hruz
Journal:  J Biol Chem       Date:  2014-04-04       Impact factor: 5.157

Review 4.  Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.

Authors:  Absalon D Gutierrez; Ashok Balasubramanyam
Journal:  Endocrine       Date:  2011-12-02       Impact factor: 3.633

5.  Trends in diabetes incidence and associated risk factors among people with HIV in the current treatment era.

Authors:  Gabriel Spieler; Andrew O Westfall; Dustin M Long; Andrea Cherrington; Greer A Burkholder; Nicholas Funderburg; James L Raper; Edgar T Overton; Amanda L Willig
Journal:  AIDS       Date:  2022-08-10       Impact factor: 4.632

6.  Antiretroviral therapy modifies the genetic effect of known type 2 diabetes-associated risk variants in HIV-infected women.

Authors:  Melissa A Frasco; Roksana Karim; David Van Den Berg; Richard M Watanabe; Kathryn Anastos; Mardge Cohen; Stephen J Gange; Deborah R Gustafson; Chenglong Liu; Phyllis C Tien; Wendy J Mack; Celeste L Pearce
Journal:  AIDS       Date:  2014-07-31       Impact factor: 4.177

Review 7.  Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.

Authors:  Ovidiu Galescu; Amrit Bhangoo; Svetlana Ten
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

Review 8.  The Increase of HIV-1 Infection, Neurocognitive Impairment, and Type 2 Diabetes in The Rio Grande Valley.

Authors:  Roberto De La Garza; Hansapani Rodrigo; Francisco Fernandez; Upal Roy
Journal:  Curr HIV Res       Date:  2019       Impact factor: 1.581

9.  Cardiovascular risk in an HIV-infected population in India.

Authors:  Ivan P Marbaniang; Dileep Kadam; Rohan Suman; Nikhil Gupte; Sonali Salvi; Sandesh Patil; Dhananjay Shere; Prasad Deshpande; Vandana Kulkarni; Andrea Deluca; Amita Gupta; Vidya Mave
Journal:  Heart Asia       Date:  2017-06-30

10.  HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4.

Authors:  Richard C Hresko; Paul W Hruz
Journal:  PLoS One       Date:  2011-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.